Autopsy report · NCT01147536

Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence

“Sponsor's business decision”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 5 months before it stopped.
• 12 participants enrolled.
• Results were posted on the registry 9 years after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Agenus Inc.

Sponsor type

Industry

Conditions

Renal Cell Carcinoma

Interventions

HSPPC-96

Participants

12

Sites

3

Countries

Canada, United States

Trials that died the same way

• Novum Vitrium® Cervical Cage in Anterior Cervical Discectomy and Fusion
  “Sponsor business decision” (97% match in meaning)
• Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker
  “business decision by sponsor” (96% match in meaning)
• INTERCEPT Safety Evaluation on Whole Blood
  “Sponsor's decision” (94% match in meaning)
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients With HLH
  “Sponsor Decision” (93% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.